A Phase 1b/2 Study of Tinengotinib (TT-00420) Plus Standard Treatments in People With Advanced Prostate Cancer


Full Title

A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)


Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called metastatic castration-resistant prostate cancers (mCRPC).

In this study, researchers want to find the best dose of tinengotinib (TT-00420) to give with standard prostate cancer treatments. The people in this study have mCRPC. It is hoped that giving tinengotinib with standard treatments will work better against prostate cancer. The standard treatments are abiraterone acetate and prednisone or enzalutamide.

Tinengotinib blocks proteins that play a role in cancer cell growth and survival. By blocking these proteins, tinengotinib may help slow or stop the growth of your cancer. Tinengotinib and the standard treatments are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have mCRPC that keeps growing even though you took enzalutamide or abiraterone acetate.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Wassim Abida’s office at 646-442-4633.




Phase I/II (phases 1 and 2 combined)



ClinicalTrials.gov ID